Unknown

Dataset Information

0

Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China.


ABSTRACT:

Background and objective

Irritable Bowel Syndrome (IBS) has a substantial impact on health-related quality of life (HR-QoL) but high-quality data pre- and post-treatment using the IBS-Quality of Life (IBS-QOL) measure are limited. The objective of this study was to evaluate the changes from baseline of the IBS-QOL scores, symptom scores and health economic data in IBS patients, after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide.

Methods

This was a prospective observational cohort study in patients with IBS, diagnosed using the Rome III criteria in four countries (Poland, Egypt, Mexico and China).

Results

A total of 607 patients were enrolled. At baseline, the IBS-QOL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China and 56.4 overall. Increases in IBS-QOL total score were statistically significant at Weeks 4 and 8 overall and in each country (overall: 11.8 at Week 4, 24.3 at Week 8; p < 0.001). Improvements were shown in all IBS-QOL subscales and scores. Symptoms and health economic outcomes were improved. Furthermore, the favourable safety profile of these treatments was confirmed in this study.

Conclusions

This study demonstrated that IBS patients have a substantially reduced HR-QoL and that treatment with mebeverine hydrochloride or pinaverium bromide improved HR-QoL.

SUBMITTER: Hou X 

PROVIDER: S-EPMC4210642 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China.

Hou Xiaohua X   Chen Shengliang S   Zhang Yali Y   Sha Weihong W   Yu Xiaofeng X   Elsawah Hesham H   Afifi Afifi Fahmy AF   El-Khayat Hisham Raafat HR   Nouh Alaa A   Hassan Mohamed Fathalla MF   Fatah Ayman Abdel AA   Rucker Joerg Isabel I   Sánchez Núñez Juan Manuel JM   Osthoff Rueda Rodolfo R   Jurkowska Grazyna G   Walczak Michal M   Malecka-Panas Ewa E   Linke Krzysztof K   Hartleb Marek M   Janssen-van Solingen Gwendolyn G  

Clinical drug investigation 20141101 11


<h4>Background and objective</h4>Irritable Bowel Syndrome (IBS) has a substantial impact on health-related quality of life (HR-QoL) but high-quality data pre- and post-treatment using the IBS-Quality of Life (IBS-QOL) measure are limited. The objective of this study was to evaluate the changes from baseline of the IBS-QOL scores, symptom scores and health economic data in IBS patients, after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide.<h4>Methods</h4>This was a  ...[more]

Similar Datasets

| S-EPMC3895767 | biostudies-literature
| S-EPMC1832201 | biostudies-literature
| S-EPMC3918199 | biostudies-other
| S-EPMC5042818 | biostudies-literature
| S-EPMC6852246 | biostudies-literature
| S-EPMC6486941 | biostudies-literature
| S-EPMC8960586 | biostudies-literature
| S-EPMC7300023 | biostudies-literature
| S-EPMC4265392 | biostudies-literature
| S-EPMC9150765 | biostudies-literature